BATIMASTAT

SynDRA canonical compound SYN0001165 — structure-anchored drug synonym record

Clinical phase	Phase 3
Primary target(s)	ADAM28 \| ADAMTS5 \| MMP1 \| MMP12 \| MMP16 \| MMP2 \| MMP8
Mechanism of action	matrix metalloprotease inhibitor

All known targets

BB-94
BB94
BB 94
Batimastat (BB-94)
UNII-BK349F52C9
Batimastat(BB-94)
C23H31N3O4S2
CHEMBL279786
BK349F52C9
Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))-
4-(N-HYDROXYAMINO)-2R-ISOBUTYL-2S-(2-THIENYLTHIOMETHYL)SUCCINYL-L-PHENYLALANINE-N-METHYLAMIDE
(2S,3R)-5-Methyl-3-(((alphaS)-alpha-(methylcarbamoyl)phenethyl)carbamoyl)-2-((2-thienylthio)methyl)hexanohydroxamic acid
Batimastat (MMP Inhibitor)
(2S,3R)-N-hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(thiophen-2-ylsulfanylmethyl)butanediamide
Butanediamide, N4-hydroxy-N1-[(1S)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]-, (2R,3S)-
(2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl)-2-((thiophen-2-ylthio)methyl)succinamide
(2r,3s)-n4-hydroxy-n1-[(1S)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]butanediamide
SMR002530309
Batimastat [USAN:INN:BAN]
MFCD00866533
1rm8
BATIMASTAT [MI]
BATIMASTAT [INN]
Batimastat (USAN/INN)
BATIMASTAT [USAN]
BATIMASTAT; BB94
BATIMASTAT [MART.]
SCHEMBL4332
MLS006010631
MLS006011226
GTPL5145
Batimastat, >=98% (HPLC)
DTXSID20156497
ISV-120
ISV-615
2j83
BB94, BB-94
EX-A1671